Intralesional steroids are the most commonly used treatment for alopecia areata, yet much remains unknown about the risks and benefits of different doses of intralesional steroids. The goal of this study is to answer some of those questions.

We are seeking men & women, at least 18 years old, to participate in a research study of intralesional injections of steroids versus inactive saline (salt water) for the treatment of Alopecia areata.

Those who qualify should be diagnosed with patch-type alopecia areata with 50% or less hair loss and a current episode lasting at least 3 months in duration. Patients with a history of alopecia totalis or universalis may be considered if hair loss is currently 50% or less.

Study participants would have monthly visits for scalp and hair examinations and scalp injections. Scalp biopsies and blood draws would occur at the first visit, week 4, 12, 24, and as well as possibly at additional timepoints.

Injection groups will be randomly assigned to intralesional triamcinolone 2.5mg injections (IL-TAC), IL-TAC 5mg injections, IL-TAC 10mg injections, or saline (placebo) injections. Injections occur every 4 weeks for 6 months.

There will be a 6 month follow up after the treatment period of 6 months for a total of 12 months study duration. During the follow up period, participants will be seen every 6 weeks and examined for hair loss/growth. Participants that did not experience regrowth of hair during the treatment period may be offered either IL-TAC 2.5mg, 5mg or 10mg if deemed appropriate by the study physician(s).

Contact:
- Department of Dermatology Clinical Research Unit
- Telephone: 212-305-6953
- Email: gu2102@columbia.edu